Elutia logo
Elutia
ELUT | NASDAQ
Chart Builder DCF Calculator
$0.82
$0.00 (0.00%)
At close: Nov 16, 2026, 4:00 PM ET
$0.82
$0.00 (+0.35%)
After-hours: Nov 16, 2026, 4:10 PM ET

Elutia Company Profile

Company profile explained

Company Profile

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Key Executives

Name Position
C. Randal Mills Co-Founder, President, Chief Executive Officer & Director
Matthew Ferguson Chief Financial Officer
Dwayne Montgomery Head of Cardiovascular
Jeffry D. Hamet Senior Vice President of Finance, Treasurer & Secretary
Michelle LeRoux Williams Chief Scientific Officer
Pete J. Ligotti Chief Commercial Officer
Sonali Fonseca Vice President & Head of Emerging Businesses
Tamara Grossett Head of People

Latest SEC Filings

Date Type Title
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
Aug 21, 2026 8-K Current Report
Aug 14, 2026 S-8 Filing
Aug 14, 2026 10-Q Quarterly Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 8-K Current Report
Aug 11, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 07, 2026 8-K Current Report
View All SEC Filings ➞
Elutia
Elutia logo
Country United States
IPO Date Oct 7, 2020
Industry Biotechnology
Sector Healthcare
Employees 26
CEO C. Randal Mills

Contact Details

20 Firstfield Road Gaithersburg, Maryland 20878 United States

Stock Details

Ticker Symbol ELUT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001708527
CUSIP Number 05479K106
ISIN Number US05479K1060
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.